SAB Biotherapeutics Inc Ordinary Shares SABS 深 滬
已收盤 02-06 16:00:00 美东时间
4.17
+0.190
+4.77%
華盛通- 最 高4.28
- 今 開3.94
- 成交量 38.39万股
- 最 低 3.75
- 昨 收 3.98
- 總市值 1.99亿
- 52周最高 6.60
- 市盈率 靜 --
- 換手率 0.81%
- 52周最低 1.00
- 委 比 -8.76%
- 總股本 4760.69万
- 歷史最高 129.00
- 量 比 1.22
- 振 幅 13.32%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
UBS Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $7
UBS analyst Michael Yee initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $7.
01-08 04:28
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
SAB Biotherapeutics Announces Confirmatory Data From Phase 1 Trial Of SAB-142 In Single- And Multiple-Ascending Dose Among Healthy Volunteers, Including Re-Dosed Cohort, And T1D Patients
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing of SAB-142 in
2025-12-17 21:05
SAB Biotherapeutics To Highlight Data Showcasing Progress In Development Of SAB-142 At ATTD-Asia
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced
2025-12-08 21:11
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.
2025-11-17 20:13
SAB Biotherapeutics To Present Phase 1 Data Demonstrating SAB-142's Multi-Specific Mechanism Of Action, Sustained Immunomodulation, Favorable Safety Profile Without Serum Sickness Or Anti-Drug Antibodies, And A Novel Pharmacokinetic Assay For Measuring The Drug
SAb Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that
2025-11-04 21:37
SAB Biotherapeutics Board Members Resign in Agreement
SAB Biotherapeutics ( ($SABS) ) has provided an announcement. On September 30, ...
2025-10-01 04:59
SAB Biotherapeutics Approves Equity Plan Amendments
SAB Biotherapeutics ( ($SABS) ) has issued an announcement. On September 26, 20...
2025-09-27 05:16
